The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Objective responses to chemotherapy in recurrent glioma: A prospective analysis from the German Glioma Network.
O. Baehr
No relevant relationships to disclose
B. Hentschel
No relevant relationships to disclose
E. Hattingen
No relevant relationships to disclose
S. Nussbaum
No relevant relationships to disclose
H. Berger
No relevant relationships to disclose
M. Tatagiba
No relevant relationships to disclose
J. C. Tonn
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Expert Testimony - Merck Serono; Roche
O. Schnell
No relevant relationships to disclose
M. Simon
No relevant relationships to disclose
T. Reithmeier
No relevant relationships to disclose
D. Krex
No relevant relationships to disclose
T. Pietsch
No relevant relationships to disclose
G. Reifenberger
Honoraria - Merck Sharp & Dohme; Roche
O. Heese
No relevant relationships to disclose
M. Weller
Honoraria - Merck Sharp & Dohme; Roche
Research Funding - Roche
J. Steinbach
Consultant or Advisory Role - Roche
Honoraria - Merck Sharp & Dohme
M. Loeffler
No relevant relationships to disclose